Literature DB >> 18157622

Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs.

Fanny Vaillant1, Panayota Tsibiribi, Giampiero Bricca, Bernard Bui-Xuan, Anne Bescond-Jacquet, Alain Tabib, Jacques Descotes, Quadiri Timour.   

Abstract

PURPOSE: Ventricular fibrillation (VF) is a possible consequence of brief myocardial ischemia. Such a short ischemia does not provoke cell damage, but induces changes in intracellular cardiac metabolism due to diminished oxygen supply to the heart. Trimetazidine (TMZ) is a drug able to restore the metabolic balance between fatty acid and glucose oxidation in ischemic myocardial cells. The aim of this double-blind study was to investigate TMZ effect on VF in pigs during short-term ischemia.
METHODS: Ischemia was induced after thoracotomy by complete, but brief (1 min) occlusion of the left anterior descending coronary artery under electrical stimulation. The ventricular fibrillation threshold (VFT), heart rate (HR), various hemodynamic parameters and malondialdehyde (MDA) blood levels were measured before and during ischemia in two groups of eight anesthetized pigs. The mass of ischemic myocardial tissue was also evaluated.
RESULTS: No effects on either the HR or the hemodynamic parameters were observed during myocardial ischemia, whereas TMZ increased the VFT and decreased both MDA blood levels (an index of lipid peroxidation) and the ischemic area.
CONCLUSIONS: TMZ limited ischemia-induced electrical dysfunction leading to cardiac susceptibility to VF by decreasing lipid peroxidation and maintaining ionic homeostasis. TMZ could therefore provide protection against ischemia-induced VF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18157622     DOI: 10.1007/s10557-007-6076-5

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  3 in total

Review 1.  Trimetazidine and Other Metabolic Modifiers.

Authors:  Giacinta Guarini; Alda Huqi; Doralisa Morrone; Paola Francesca Giuseppina Capozza; Mario Marzilli
Journal:  Eur Cardiol       Date:  2018-12

2.  Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

Authors:  Sheik Wisel; Mahmood Khan; M Lakshmi Kuppusamy; I Krishna Mohan; Simi M Chacko; Brian K Rivera; Benjamin C Sun; Kálmán Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

3.  Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.

Authors:  L Dehina; F Vaillant; A Tabib; B Bui-Xuan; Ph Chevalier; N Dizerens; C Bui-Xuan; J Descotes; V Blanc-Guillemaud; L Lerond; Q Timour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-22       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.